Cardiac functions evaluated with tissue doppler imaging in childhood cancers treated with anthracyclines

Pediatric Hematology and Oncology

Volumn 27, Issue 1, 2010, Pages 13-23

  Baysal, Tamer ^a   Koksal, Yavuz ^a   Oran, Bulent ^a   Sen, Metin ^a   Unal, Ekrem ^a   Cimen, Derya ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Anthracyclines; Childhood cancers; Tissue Doppler imaging

Indexed keywords

DOXORUBICIN;

A WAVE; ACUTE HEART FAILURE; ADOLESCENT; ADULT; ARTICLE; BODY SURFACE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DRUG FATALITY; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART RIGHT VENTRICLE FUNCTION; HEPATOBLASTOMA; HODGKIN DISEASE; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PULSE WAVE; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; DIASTOLE; DOXORUBICIN; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HEMODYNAMICS; HUMANS; INFANT; MALE; NEOPLASMS; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 76649119812     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880010903352299     Document Type: Article

References (43)

1. Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol. 2000;12:146-152.
2. Boucek RJ. Mechanisms for anthracyline-induced cardiomyopathy: clinical and laboratory correlations. Prog Pediatr Cardiol. 1998;8:59-70.
3. Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistant effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol. 1999;31:1435-1446.
4. Senju N, Ikeda S, Koga S, et al. The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels. 2007;22:393-397.
5. Ocal B, Oguz D, Karademir S, et al. Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol. 2002;23:522-527.
6. Burke BE, Olson RD, Cusack BJ, Gambliel HA, Dillmann WH. Anthracycline cardiotoxicity in transgenic mice overexpressing SR Ca2+- ATPase. Biochem Biophys Res Commun. 2003;303:504-507.
7. Sung RY, HuangGY, ShingMK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol. 1997;60:239-248.
8. Yu WC, Lee WS, Huang WP, Wu CC, Lin YP, Chen CH. Evaluation of cardiac function by tissue Doppler echocardiography: hemodynamic determinants and clinical application. Ultrasound Med Biol. 2005;31:23-30.
9. Sahn DJ, De Maria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography: results of echocardiographic measurements. Circulation. 1978;58:1072-1083.
10. Tavil Y, Ureten K, Ozturk MA, et al. The detailed assessment of left and right ventricular functions by tissue Doppler imaging in patients with familial Mediterranean fever. Clin Rheumatol. 2008;27:189-194.
11. Rakowski H, Appleton C, Chan KL, et al. (1996) Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiograhy. J Am Soc Echocardiogr. 9:736-760.
12. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995;26:396-404.
13. Lewitt G. Cardioprotection. Br J Haematol. 1999;106:860-869.
14. Lewitt GA,Dorup I, Sorensen K, Sullivan I.Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol. 2004;124:463-468.
15. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr. 2001;160:607-610.
16. Moyssakis I, Moschos N, Triposkiadis F, et al. Left ventricular end-systolic stress/diameter relation as a contractility index and as a predictor of survival. Independence of preload after normalization for enddiastolic diameter. Heart Vessels. 2005;20:191-198.
17. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics. 1992;89:942-949.
18. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sander SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
19. Hausdorf G,Morf G, Beron G, Erttmann R,Winkler K, Landbeck Keck EW. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 1988;60:309-315.
20. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J.1989;118:92-98.
21. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87:1120-1122. (Pubitemid 32710333)
22. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62-69.
23. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol. 1999;20:252-263.
24. Bu'Lock FA, Mott MG, Oakhill A, et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996;75:416-422.
25. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. Am J Coll Cardiol. 1987;9:184-188.
26. Bruch C, Schmermund A, Marin D, et al. Tei index in patients with mild-to-moderate congestive heart failure. Eur Heart J. 2000;21:1888-1895.
27. Acil T, Wichter T, Stypmann J, et al. Prognostic value of tissue Doppler imaging in patients with chronic congestive heart failure. Int J Cardiol. 2005;103:175-181.
28. ChoongCY, HerrmannHC, Weyman AE, Fifer MA. Preload dependence ofDoppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol. 1987;10:800-808.
29. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27:53-68.
30. Lipshultz SE, Colan SD. The use of echocardiography and holter monitoring in the assessment of anthracycline-treated patients. In:Bricker JT, Green DM, Dangio GJ, eds. Cardiac Toxicity after Treatment for Childhood Cancer. New York:Wiley-Liss;1993:45-62.
31. Kapusta L, Thijssen JM, Cuypers MH, et al. Assessment of myocardial velocities in healthy children using tissue Doppler imaging. Ultrasound Med Biol. 2000;26:229-237.
32. Kapusta L, Groot-Loonen J, Thijssen JM, DeGraaf R, Danis̈els O. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol. 2003;41:426-435.
33. Harada K, Tamura M, Toyono M, Yasuoka K. Comparison of the right ventricular Tei index by tissue Doppler imaging to that obtained by pulsed Doppler in children without heart disease. Am J Cardiol. 2002;90:566-569.
34. Rojo EC, Rodrigo JL, Ṕerez de Isla L, et al. Disagreement between tissue Doppler imaging and conventional pulsed wave Doppler in the measurement of myocardial performance index. Eur J Echocardiogr. 2006;7:356-364.
35. Meinardi MT, Van DerGraaf WT, van VeldhuisenDJ, Gietema JA, de Vries EG, Sleijfer DT.Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237-247.
36. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544-1552. (Pubitemid 27167391)
37. Torti FM, BristowMR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745-749.
38. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy-risk factors. Cancer. 1977;39:1397-1402.
39. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
40. Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;62:1381-1385.
41. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
42. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.
43. Villani F, Comazzi R, Lacaita G, et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother. 1985;2:93-97.